Page last updated: 2024-09-05

5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepin-7-ol and clozapine n-oxide

5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepin-7-ol has been researched along with clozapine n-oxide in 1 studies

Compound Research Comparison

Studies
(5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepin-7-ol)
Trials
(5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepin-7-ol)
Recent Studies (post-2010)
(5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepin-7-ol)
Studies
(clozapine n-oxide)
Trials
(clozapine n-oxide)
Recent Studies (post-2010) (clozapine n-oxide)
13502418188

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ahlenius, S; Salmi, P1

Other Studies

1 other study(ies) available for 5-(2,3-dihydrobenzofuran-7-yl)-3-methyl-8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepin-7-ol and clozapine n-oxide

ArticleYear
Further evidence for clozapine as a dopamine D1 receptor agonist.
    European journal of pharmacology, 1996, Jun-20, Volume: 307, Issue:1

    Topics: Animals; Benzazepines; Benzofurans; Body Temperature; Clozapine; Dopamine Agonists; Dopamine Antagonists; Male; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Sensitivity and Specificity

1996